List of Excipients in Branded Drug MYTESI

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Napo Pharmaceuticals Inc	MYTESI	crofelemer	70564-802	CELLULOSE, MICROCRYSTALLINE	2031-10-31
Napo Pharmaceuticals Inc	MYTESI	crofelemer	70564-802	CROSCARMELLOSE SODIUM	2031-10-31
Napo Pharmaceuticals Inc	MYTESI	crofelemer	70564-802	ETHYL ACRYLATE	2031-10-31
Napo Pharmaceuticals Inc	MYTESI	crofelemer	70564-802	MAGNESIUM STEARATE	2031-10-31
Napo Pharmaceuticals Inc	MYTESI	crofelemer	70564-802	METHYLPARABEN	2031-10-31

Mytesi Excipient Strategy and Commercial Opportunities for Crofelemer

Last updated: October 6, 2026

Mytesi is a 125 mg delayed-release tablet containing crofelemer, a botanical drug approved by the FDA for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy [1]. Its excipient strategy supports gastrointestinal delivery, tablet robustness, delayed release, and long-term commercial handling rather than systemic absorption.

The strongest commercial opportunities are reformulated oral presentations, lower-cost generic or authorized-generic supply, international registration, institutional HIV care, and expansion into additional secretory-diarrhea indications. The main technical barrier is reproducing the product’s release profile and clinical performance, not simply matching the active ingredient.

What is Mytesi and how does its formulation work?

Mytesi contains crofelemer, a purified botanical drug derived from the red latex of Croton lechleri. Crofelemer acts locally in the intestinal lumen by inhibiting chloride secretion through CFTR and calcium-activated chloride channels. It has minimal systemic absorption, which differentiates it from many centrally acting or systemically absorbed antidiarrheal drugs [1].

The product is supplied as a 125 mg delayed-release tablet. The delayed-release design is commercially important because it places the active ingredient in the gastrointestinal tract while limiting premature release and supporting local activity.

Mytesi formulation profile

Attribute	Mytesi profile
Active ingredient	Crofelemer
Strength	125 mg
Dosage form	Delayed-release tablet
Route	Oral
Primary mechanism	Inhibition of intestinal chloride secretion
Systemic exposure	Minimal
FDA indication	Noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
Approved dosage	125 mg twice daily
Primary formulation objective	Local gastrointestinal delivery
Commercial owner	Jaguar Health through its Napo Pharmaceuticals subsidiary
FDA approval	December 31, 2012

The product’s local mechanism creates formulation flexibility, but any new presentation must preserve intestinal exposure, tolerability, dose uniformity, and the clinically relevant delayed-release behavior.

What excipients are used in Mytesi?

FDA labeling identifies Mytesi’s inactive ingredients as microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, talc, and triacetin [1].

The public label does not establish the precise grade, supplier, particle-size distribution, processing order, or quantitative concentration of each excipient. Those variables can materially affect tablet hardness, disintegration, coating performance, stability, and bioequivalence.

Functional role of the principal excipients

Excipient	Likely formulation role
Microcrystalline cellulose	Tablet diluent and compression aid
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and moisture-control aid
Magnesium stearate	Lubricant
Hypromellose	Film-forming polymer and coating component
Titanium dioxide	Opacifier and pigment
Talc	Anti-tacking and coating-processing aid
Triacetin	Plasticizer for the film coating

The formulation uses conventional oral solid-dose excipients. That lowers raw-material procurement risk and supports contract manufacturing. It also means that the formulation itself may be difficult to protect broadly through composition-of-matter claims unless the applicant can establish a specific release, stability, or performance advantage.

What excipient strategy protects Mytesi’s commercial performance?

The most important excipient strategy is functional, not merely compositional.

Delayed-release control

A delayed-release product must control exposure to gastric conditions and release crofelemer at the intended intestinal site. The coating system, polymer grade, coating weight, plasticizer level, and process conditions affect:

• Acid resistance
• Intestinal release
• Tablet-to-tablet uniformity
• Mechanical durability
• Moisture sensitivity
• Shelf-life performance
• Food-effect behavior

A generic manufacturer could use different excipients while achieving the same release profile. Conversely, a formulation that copies the listed ingredients but produces a different dissolution curve may face regulatory and commercial problems.

Tablet disintegration

Crofelemer is administered locally, so the dosage form must release an adequate amount of active drug in the intestinal tract. Microcrystalline cellulose and croscarmellose sodium support tablet breakup after the enteric or delayed-release barrier has dissolved.

Excessive compression force, high lubricant levels, or an over-dense tablet core could delay disintegration. Excessive disintegration can also undermine mechanical strength and coating integrity.

Moisture and coating stability

The presence of a film coating creates a manufacturing-control requirement. Moisture uptake can alter tablet hardness, coating adhesion, and release behavior. Colloidal silicon dioxide can improve powder flow and reduce processing variability, while a controlled packaging system can protect the product during distribution.

Blister packaging, high-barrier bottles, desiccants, and validated humidity controls are potential lifecycle tools. Packaging is particularly relevant in tropical and emerging markets where supply-chain humidity can be high.

Botanical-drug quality control

Crofelemer is a botanical drug, so excipients are only one element of product consistency. The manufacturer must control botanical raw material, extraction, purification, chemical fingerprinting, impurities, microbial quality, and batch comparability. FDA botanical-drug guidance treats raw-material and process consistency as central to product quality [2].

For this reason, a competing product may face greater development complexity than a conventional synthetic generic, even if the finished dosage form appears simple.

What commercial opportunities exist for Mytesi reformulation?

The largest opportunities involve convenience, adherence, procurement economics, and expansion beyond the current HIV market.

Sprinkle or dispersible presentation

A sprinkle formulation could support patients with dysphagia, swallowing limitations, or medication fatigue. The technical challenge is preserving delayed release after the tablet is opened, crushed, or dispersed. An enteric-coated multiparticulate system could be more suitable than a conventional crushed tablet.

Potential commercial advantages include:

• Improved administration for patients with swallowing difficulties
• Use in long-term-care settings
• Reduced dependence on swallowing an intact tablet
• Potential pediatric and geriatric positioning
• Differentiation from standard generic tablets

The regulatory risk is substantial. A new sprinkle product would need to establish dose uniformity, stability after opening, compatibility with soft foods or liquids, and equivalent clinical performance.

Oral suspension or sachet

A liquid or sachet presentation could address patients unable to swallow tablets and facilitate institutional dispensing. Crofelemer’s low systemic absorption makes a local GI suspension concept scientifically plausible, but a liquid product would introduce new challenges:

• Chemical and microbiological stability
• Sedimentation or aggregation
• Dose uniformity
• Palatability
• Preservative tolerance
• Container-closure compatibility
• Maintenance of delayed release

An immediate-release suspension may not reproduce the performance of Mytesi. A pH-dependent or coated-particle suspension would likely be more technically aligned with the existing product.

Lower-cost standard tablet

The most commercially realistic opportunity is a conventional delayed-release tablet made with widely available excipients. This pathway could reduce cost of goods and expand access through public-health procurement, managed-care formularies, and international tenders.

The primary development hurdle is comparative dissolution across acidic and intestinal media. A generic sponsor would also need to address the regulatory pathway applicable to a botanical drug and demonstrate pharmaceutical equivalence and bioequivalence where required.

Pediatric formulation

HIV-associated diarrhea remains relevant in pediatric populations, but a pediatric crofelemer product would require more than simply reducing tablet size. Suitable options could include:

• Lower-strength delayed-release tablets
• Multiparticulates
• Sprinkle capsules
• Coated granules
• A reconstituted product with enteric protection

Pediatric development would expand the addressable market but would require age-appropriate dosing, palatability, administration studies, and pediatric pharmacology.

What patent and regulatory protections affect Mytesi?

Mytesi’s original FDA exclusivity is no longer the principal commercial barrier. The drug was approved in 2012, and the statutory exclusivity period associated with the original approval has expired under the standard Hatch-Waxman framework [3].

Orange Book status

Mytesi’s current regulatory position should be evaluated through the FDA Orange Book for:

• Listed patents
• Patent-use codes
• Product reference-standard status
• Generic application activity
• Paragraph IV certifications
• Any remaining pediatric or other exclusivity

The Orange Book is the controlling public source for listed patents and FDA-recognized exclusivity. Patent listings should not be treated as equivalent to enforceable broad protection. Their practical value depends on claim scope, expiration, use-code precision, prosecution history, and litigation outcomes [4].

Paragraph IV risk

A generic applicant can challenge listed patents through a Paragraph IV certification. A certification can trigger Hatch-Waxman litigation if the patent holder files suit within the statutory period. The commercial consequences depend on:

• Whether a listed patent remains in force
• Whether the patent claims the product, formulation, or method of use
• Whether the proposed label includes the patented indication
• Whether the applicant pursues a section viii statement
• Whether the patent holder obtains an injunction
• Whether a settlement restricts launch timing

A method-of-use patent may be less effective if a generic can use a label that omits the patented indication while retaining approval for an unpatented use. Product and formulation claims generally present a stronger barrier because they can reach the dosage form itself.

Biosimilar risk

Biosimilar risk is not material for Mytesi. Crofelemer is a small-molecule botanical drug administered as an oral tablet, not a therapeutic protein or other biologic subject to the biosimilar pathway. Competitive entry would occur through generic, 505(b)(2), or other applicable small-molecule pathways rather than under the Biologics Price Competition and Innovation Act [5].

What is the strength of the Mytesi patent estate?

The commercial strength of the Mytesi estate is likely moderate rather than absolute.

The active ingredient is an established botanical substance, which limits the ability to rely on a conventional new-molecule composition patent. Protection is more likely to depend on:

• Specific therapeutic uses
• Dosage regimens
• Purification or manufacturing processes
• Formulation and release characteristics
• Pharmaceutical compositions
• Combination use with antiretroviral therapy
• Product-specific quality attributes

Patent-strength assessment

Protection category	Likely strength	Commercial relevance
Crofelemer itself	Limited to moderate	Botanical identity reduces broad composition protection
Delayed-release formulation	Moderate if claims are narrow and validated	Relevant to generic substitution
Method of treating HIV-associated diarrhea	Moderate	Can support indication protection
Manufacturing process	Moderate	May create technical barriers but can be designed around
Excipient combination alone	Low to moderate	Stronger only if tied to measurable performance
Botanical source and quality controls	Moderate	Important for supply and consistency
New delivery system	Potentially strong	Supports lifecycle management and differentiated pricing

An excipient patent that merely lists common materials is unlikely to create durable exclusion. A stronger claim would connect a defined excipient system to a measurable result, such as acid resistance, intestinal dissolution, stability, reduced variability, or improved administration.

Which companies could challenge or compete with Mytesi?

Competition is likely to come from several categories rather than one direct substitute.

Generic crofelemer manufacturers

A generic entrant would target the 125 mg delayed-release tablet. Its main advantages would be lower price and formulary leverage. Development risk would center on:

• Botanical active-ingredient sourcing
• Batch comparability
• Release testing
• Bioequivalence strategy
• Manufacturing scale
• Stability under global distribution conditions

Conventional antidiarrheal products

Loperamide, diphenoxylate-atropine, bismuth products, and dietary or supportive therapies compete for treatment decisions. These products may be cheaper and more familiar, but they do not duplicate crofelemer’s local antisecretory mechanism.

Mytesi’s commercial positioning is strongest where diarrhea persists despite antiretroviral treatment, where drug-drug interaction concerns influence selection, or where long-term symptom management is needed.

Pipeline and indication competitors

Crofelemer has potential value in other secretory-diarrhea settings, including cancer-treatment-related diarrhea, irritable bowel syndrome with diarrhea, inflammatory or infectious conditions, and other chronic intestinal disorders. Each expansion would require clinical evidence and could create new method-of-use and formulation opportunities.

The opportunity is commercially attractive only if the company can secure reimbursement and demonstrate a clinically differentiated benefit over low-cost antidiarrheals.

How can excipients create licensing and partnership opportunities?

Excipient-driven licensing is most credible when it delivers a defined product advantage. Potential partners include:

• Specialty generic manufacturers
• Contract development and manufacturing organizations
• Pediatric formulation companies
• Oral multiparticulate technology providers
• Regional pharmaceutical companies
• Public-health suppliers
• Specialty gastrointestinal companies

A licensable asset could include a coated multiparticulate system, a room-temperature-stable liquid, a pediatric sprinkle formulation, or a high-throughput manufacturing process with lower coating costs.

The strongest deal structure would link royalties or milestones to regulatory approval, commercial launch, and sales thresholds. A simple license to common excipients would have limited value unless the license includes proprietary process know-how, validated release specifications, or a protected dosage form.

What generic launch scenarios exist for Mytesi?

Scenario	Timing driver	Market effect
No near-term generic	Patent, regulatory, or technical barriers	Maintains branded pricing
Single generic entrant	Approval and limited competition	Moderate price erosion
Multiple tablet entrants	Rapid ANDA or equivalent approvals	Significant price compression
Authorized generic	Brand-controlled launch	Preserves channel access and limits third-party share
Reformulated competitor	New dosage form or 505(b)(2) strategy	May avoid direct tablet competition
International launch	Local registration and supply economics	Expands volume but lowers net price

The most disruptive scenario is multiple manufacturers achieving equivalent delayed-release performance. In that case, the excipient list alone would provide little protection, and supply-chain cost, regulatory execution, and payer contracting would determine share.

What is the revenue opportunity for Mytesi?

Mytesi’s addressable opportunity is larger than its original HIV-associated diarrhea niche, but expansion depends on evidence and reimbursement.

Near-term opportunities

Near-term commercial growth can come from:

1. Improving adherence and administration.
2. Securing institutional and public-health contracts.
3. Expanding international distribution.
4. Developing a lower-cost tablet.
5. Creating an authorized generic strategy.
6. Building specialty-pharmacy and infectious-disease channel coverage.

Longer-term opportunities

Longer-term value depends on new indications. Cancer-treatment-related diarrhea is a potentially important market because patients may require repeated management and may have limited tolerance for systemic antidiarrheals. A successful indication expansion could support new method-of-use patents, payer contracts, and commercial partnerships.

The main financial risk is that new indications require expensive clinical development while generic or conventional antidiarrheal competition limits pricing power.

Key Takeaways

• Mytesi is a 125 mg crofelemer delayed-release tablet approved for noninfectious diarrhea in adults with HIV/AIDS.
• Its excipient system uses conventional tablet and film-coating materials, including microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, talc, and triacetin.
• The commercial value of the formulation lies in delayed-release performance, not in the use of any single common excipient.
• Original FDA exclusivity has expired; current patent and generic risk depend on the live Orange Book record and enforceable claim scope.
• Biosimilar competition does not apply because crofelemer is an oral botanical small-molecule drug.
• The most credible lifecycle opportunities are sprinkle formulations, multiparticulates, pediatric products, liquid systems, international products, and lower-cost delayed-release tablets.
• Generic development is technically feasible but must address botanical consistency, dissolution, stability, and regulatory pathway requirements.
• New indications, especially treatment-related diarrhea, offer the greatest upside but require clinical evidence and reimbursement support.

FAQs About Mytesi Excipients and Commercial Strategy

Can Mytesi tablets be crushed or mixed with food?

The approved labeling should control administration. A delayed-release tablet should not be assumed to retain performance after crushing or dispersing unless that use has been specifically evaluated.

Are Mytesi excipients patentable?

Common excipients are generally difficult to protect broadly. Patent strength improves when a defined excipient system produces a demonstrated release, stability, manufacturing, or administration benefit.

Is crofelemer eligible for a biosimilar?

No. Crofelemer is not a biologic. Competitive products would generally use generic or other small-molecule regulatory pathways.

Could a liquid Mytesi product command a premium?

Potentially, if it solves swallowing or administration problems and preserves delayed-release intestinal delivery. Stability, palatability, dose uniformity, and reimbursement would determine commercial value.

What is the most likely generic formulation for Mytesi?

The most likely entrant is a conventional 125 mg delayed-release tablet using a functionally equivalent excipient and coating system, rather than an entirely new dosage form.

References

1. U.S. Food and Drug Administration. (2023). Mytesi (crofelemer) delayed-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2016). Botanical drug development: Guidance for industry.
3. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the regulatory exclusivity provisions.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (2024). Generic drug facts and the abbreviated new drug application process.
6. Jaguar Health, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.